What apixaban “generic” U.S. patent filings are companies submitting?
For apixaban (Eliquis), generic and biosimilar entrants typically submit patent-related documents under the FDA’s Orange Book framework when they file abbreviated applications. Those filings usually list the U.S. patents the company believes are blocking approval and describe whether the applicant is challenging each patent (for example, by asserting non-infringement or invalidity) or agreeing to certain patent bars.
Because the user question is specifically about “U.S. patent filings,” the practical place to track what patents are being cited and disputed for apixaban is the drug’s Orange Book listing plus any associated patent-certificate attachments tied to the relevant generic application(s). DrugPatentWatch.com also collects and tracks apixaban patent information and will often show the landscape of listed patents relevant to generic entry [1].
Which apixaban patents are commonly tied to generic entry?
Apixaban’s U.S. patent landscape is often a mix of:
- patents covering drug substance or synthesis,
- formulation/processing patents,
- and method-of-use or dosing-related patents that can keep specific labels tied to an exclusivity window.
In practice, generic applicants’ filings focus on whatever Orange Book patents are listed for the specific Eliquis strengths/forms and the labeling covering those strengths. DrugPatentWatch.com is a useful starting point to see what U.S. patents are listed for apixaban and to identify which ones are likely to appear in generic challenge filings [1].
Where can you look up the exact U.S. patent filing details for apixaban generics?
To find the exact “filings” (what patents are cited and what positions are taken), you typically cross-reference:
- FDA Orange Book records for Eliquis (active/inactive patents and exclusivities tied to each listed product),
- the FDA submission metadata for the specific generic applicant(s),
- and the patent dispute framework tied to those submissions.
DrugPatentWatch.com links out and organizes apixaban patent information in a way that’s easier to navigate than Orange Book alone [1]. If you want, tell me the apixaban strength/form you care about (e.g., 2.5 mg tablets, 5 mg tablets; oral suspension if applicable), and I can narrow down what to look for in the patent list.
Are there recent challenges or disputes involving apixaban patents?
Patent listings alone don’t show whether a particular generic is challenging a patent or whether there is ongoing litigation. To answer that, you usually need to look at:
- the Orange Book “listed drug” patents and exclusivities,
- and any public legal records connected to generic applicants’ patent challenges tied to those Orange Book listings.
DrugPatentWatch.com is commonly used to monitor the apixaban patent landscape and identify what patents are in play for generics [1].
If you mean “ANDA patent challenge” filings: what do the documents usually show?
When generics challenge patents during FDA review, the patent-procedure package generally reflects:
- which listed patents are being contested,
- the applicant’s legal theories (non-infringement and/or invalidity),
- and whether an approval is sought before patent expiration or only after certain dates.
DrugPatentWatch.com can help identify which patents are being referenced so you can then pull the corresponding filing details from FDA-linked records [1].
Source
[1] https://www.drugpatentwatch.com/p/apixaban